US inflation exceeds expectations to hit 2.4pc
The Bank of England risks inflicting unnecessary damage to the economy by keeping interest rates too high for too long, a ...
Broker tips: GSK, Central Asia Metals
GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...
European stocks end lower after US inflation data; French budget in focus
European shares closed lower on Thursday, with defence and industrial stocks leading losses, after data showed U.S. inflation ...
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
UK stocks drag as investors cautious despite US inflation slowing
London’s FTSE 100 was down 6.01 points, or 0.07%, to close at 8,237.73, with housebuilders among the stocks dragging on the ...
Drugmaker to settle nearly 80K Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
GSK’s problem is it has more than one source of pain
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...
GSK settles vast majority of Zantac claims for $2.2 billion
The settlement will see GSK resolve around 80,000 of the Zantac claims it faces for sums well below the $30 billion worst-case scenario figure currently priced into GSK's share price, Shore Capital ...
GSK to pay $2.2bn to settle Zantac lawsuits
GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of ...